BRCA1- or BRCA2-deficient cells are sensitive to siRNA-mediated knockdown or chemical inhibition of PARP, leading to the clinical testing of PARP inhibitors as potential anti-cancer drugs in BRCA1- or BRCA2-deficient cancers. Here, BRCA2 is linked to cancer.